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Abstract
Background: In a large number of studies, members of the microRNA (miRNA)-34 family such as miRNA-34a,
miRNA-34b, miRNA-34c, as well as miRNA-125b and miRNA-155, have been shown to be regulators of apoptosis.
The ability of these miRNAs to perform this function is mainly attributed to their ability to interact with the p53
tumor suppressor, which is a powerful regulator of the teratologic susceptibility of embryos. We chose to explore
whether miRNA-34a/b/c, miRNA-125b and miRNA-155 may play a role in teratogenesis by using p53
+/- pregnant
mice treated with cyclophosphamide (CP) as a model. We evaluated how CP-induced alterations in the expression
of these miRNAs in the embryonic limbs correlate with embryonic p53 genotype and CP-induced limb
phenotypes.
Results: The limbs of p53 positive embryos were more sensitive to CP-induced teratogenic insult than the limbs of
p53 negative embryos. The hindlimbs were more severely affected than the forelimbs. Robust miRNA-34a
expression was observed in the fore- and hindlimbs of p53
+/+ embryos exposed to 12.5 mg/kg CP. The dose of 20
mg/kg CP induced almost a two-fold increase in the level of miRNA-34a expression as compared to that exhibited
by p53
+/+ embryos exposed to a lower dose. Increased miRNA-34b and miRNA-34c expression was also observed.
Of note, this dose activated miRNA-34a and miRNA-34c in the forelimbs of p53
-/- embryos. When embryos were
exposed to 40 mg/kg CP, the expression pattern of the miRNA-34a/b/c was identical to that registered in the limbs
of embryos exposed to 20 mg/kg CP. However, this dose suppressed miRNA-125b and miRNA-155 expression in
the fore- and hindlimbs of p53
+/+ embryos.
Conclusion: This study demonstrates that teratogen-induced limb dysmorphogenesis may be associated with
alterations in miRNA-34, miRNA-125b and miRNA-155 expression. It also suggests for the first time that
p53-independent mechanisms exist contributing to teratogen-induced activation of miRNA-34a and miRNA-34c. At
the same time, teratogen-induced suppression of miRNA-125b and miRNA-155 expression may be p53 dependent.
The analysis of correlations between the expression pattern of the tested miRNAs and CP induced limb
phenotypes implies that miRNAs regulating apoptosis may differ from each other with respect to their functional
role in teratogenesis: some miRNAs act to protect embryos, whereas other miRNAs boost a teratogen-induced
process of maldevelopment to induce embryonic death.
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Mature microRNAs (miRNAs) are non-coding RNAs
composed of about 22-nucleotide, that attenuate gene
activity posttranscriptionally by inhibiting effective mRNA
translation of target genes. Silencing takes place through
sequence-specific base pairing between the miR and its
target mRNAs [1,2]. By now, hundreds of miRNAs have
been detected [3] and some miRNAs have been shown to
be essential for normal embryonic development, control-
ling developmental events such as neurogenesis, angiogen-
esis, and the formation of limbs, heart and muscles [4,5].
In parallel, studies in invertebrates and various types of
cultured cells revealed the ability of some miRNAs to reg-
ulate cell proliferation and apoptosis [6,7]. These observa-
tions have formulated a basis to suggest that miRNAs may
play an important role in cancer formation, acting both as
oncogenes and tumor suppressors [8]. Remarkably, these
observations also suggest that miRNAs may act as regula-
tors of embryos’ susceptibility to developmental toxicants
(teratogens). Indeed, apoptosis and cell proliferations are
critically important processes of normal embryogenesis
[9]. Teratological studies have revealed that the appear-
ance of teratogen-induced structural anomalies is often
preceded by excessive apoptosis in embryonic structures
that are destined to be malformed [10,11]. At the same
time, teratogen-induced apoptosis is also often registered
in embryonic structures that appear normal at birth
[10,11]. This demonstrates that the embryo is able to com-
pensate for teratogen-induced cell death and, hence, tera-
tologic susceptibility of embryos depends not only on the
mechanisms regulating apoptosis but also on mechanisms
regulating cell proliferation.
Recently, a number of studies have provided compelling
evidence that members of the miRNA-34 family (hereafter
abbreviated as miRNA-34) such as miRNA-34a, miRNA-
34b and miRNA-34c are direct transcription targets of the
tumor suppressor protein p53, having the potential to reg-
ulate both apoptosis and cell proliferation [12]. The role of
p53 as a regulator of teratological susceptibility of embryos
has been demonstrated in studies with diverse teratogens
such as benzo(a)pyrene [13,14], 2-chloro-2-deoxyadeno-
sine [14], 4-hydroperoxycyclophosphamide [15], cyclopho-
sphamide [16], ionizing radiation [17,18] and diabetes [19].
Quite a few genes have been demonstrated as mediators of
p53- induced apoptosis and cell arrest [20,21], but those
acting in teratogen-exposed embryos remain largely unde-
fined. Therefore, our question was whether miRNA-34
may be among targets engaged by p53 to regulate teratolo-
gic susceptibility of embryos.
Two other miRNAs, miRNA-125b and miRNA-155
also seemed to be good candidates for the role of terato-
logic regulators. Specifically, our and others study with
cyclophosphamide (CP) have revealed that excessive
apoptosis is a major event in the pathogenesis of
CP-induced process of maldevelopment [10,22]. p53 acts
to intensify both CP-induced apoptosis and suppression
of cell proliferation [16]. It also mediates CP -induced
activation of caspase 3 and suppression of the transcrip-
tion factor NF-kB DNA binding [16]. Furthermore, our
recent work has implied that CP-induced suppression of
NF-kB signaling may be linked to CP-induced apoptosis
and suppression of cell proliferation [23]. In turn,
miRNA-155 has been shown to regulate apoptosis and
suggested to target caspases 3 and NF-kB signaling
[24,25]. MiRNA-125b has been suggested to control the
expression of the tumor necrosis factor alpha (TNFa)
[26], a cytokine, acting as a powerful activator of NF-kB
[27]. Notably, our studies have provided evidence sug-
gesting that TNFa may determine sensitivity of mice to
CP-induced teratogenic insult [28].
Given the potential involvement of miRNA-34,
miRNA-125b and miRNA-155 in the mechanisms regu-
lating teratologic susceptibility of embryos, we chose to
explore whether CP alters the expression of the miRNAs
in the embryonic limbs and how the alterations corre-
late with the embryonic p53 genotype and CP-induced
limb phenotypes. We used CP-treated p53 heterozygous
mice as a model and the fore- and hindlimbs of p53
knockout and p53 positive embryos as target embryonic
structures.
Results
Reproductive performance of CP-treated mice
In females injected with the highest dose of CP
(40 mg/kg), the level of postimplantation death of
embryos exceeded 26% (Table 1). This was a significant
increase when compared to that of females exposed to
lower doses of CP and controls. In these females a trend
to the departure from the Mendelian 25%:50%:25% geno-
type ratio (≈29%:60%:11%) due to the death of p53
-/-
embryos was also registered. In mice exposed to lower
doses of CP these indices did not differ significantly from
those in controls (Table 1).
Teratogenic response to CP
As expected, the forelimbs and hindlimbs exhibited dif-
ferential sensitivity to CP-induced teratogenic stimuli.
Indeed, practically all fetuses of mice exposed to
40 mg/kg had digit anomalies of the fore- and hindlimbs
(Table 2). At the same time, limb reduction anomalies
of the hindlimbs but not of the forelimbs were regis-
tered in these fetuses. In females exposed to 20 mg/kg,
the proportion of embryos having digit anomalies of the
forelimbs was significantly lower than that of embryos
exhibiting digit anomalies of the hindlimbs. Finally,
≈30% of embryos exposed to 12.5 mg/kg CP had digit
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malformed forelimbs (Table 2).
Effects of p53 embryonic genotype
In females exposed to 20 mg/kg, ≈38% of p53 positive
embryos had digit anomalies of the forelimbs and nearly
100% had digit anomalies of the hindlimbs (Table 3). At
the same time, no p53 negative embryos with mal-
formed forelimbs were detected and ≈14% of the
embryos had digit anomalies of the hindlimbs. Limb
reduction anomalies were also observed only in the hin-
dlimbs of p53 positive embryos (Table 3). The same
relationship between teratologic limb phenotypes and
p53 embryonic genotype was registered when mice were
exposed to other doses of CP. Thus, the limbs of p53
negative embryos of females exposed to 12.5 mg/kg CP
were normal, whereas 10% and ≈40% of p53 positive
embryos had digit anomalies of the forelimbs and hin-
dlimbs, respectively. When mice were exposed to 40
mg/kg CP, digit anomalies of the forelimbs were
observed in all p53 positive embryos and in ≈71%
of p53 negative embryos. Limb reduction anomalies
of the hindlimbs were also observed in 70% of p53
negative embryos and all p53 positive embryos. Thus,
these results demonstrate that the limbs of p53 positive
embryos are more sensitive to CP than the limbs of p53
knockout embryos, with differential teratologic sensitiv-
ity of the fore- and hindlimbs being independent on p53
embryonic genotype.
Influence of CP on miRNA-34a expression
CP at a dose of 12.5 mg/kg induced robust miRNA-34a
expression in the fore- and hindlimbs of p53
+/+ but not
in the limbs of p53
-/- embryos (Figure 1). No statistically
significant differences in miRNA-34a levels registered in
the fore- and hindlimbs were observed. When females
were treated with 20 mg/kg CP, p53
+/+ embryos exhib-
ited statistically insignificant but almost two-fold
increase in the level of miRNA-34a expression as com-
pared to that registered in the embryos exposed to the
Table 1 Reproductive performance of p53
+/- females treated with cyclophosphamide (CP) and tested on day 16 of
pregnancy.
Groups of females
Indices Control CP (12.5 mg/kg) CP (20 mg/kg) CP (40 mg/kg)
Number of pregnant females 8 10 14 10
Implantation sites/litter 66/8.3 84/8.4 106/7.6 83/8.3
Percent of resorptions
(arcsine, mean ± SE)
6.1
(16.2 ± 3.4)
a
4.8
(15.4 ± 2.5)
a
13.2
(23.5 ± 3.6)
a
26.5
(32.0 ± 2.0)
b
Number of live fetuses
Total 62 80 92 61
p53
+/+ 18 (29%) 14 (17.5%) 16 (17.4%) 18 (29.5%)
p53
+/- 27 (43.6%) 46 (57.5%) 48 (52.2%) 36 (59%)
p53
-/- 17 (27.4%) 20 (25%) 28 (30.4%) 7 (11.5%)
Superscripts denote results of statistical analysis of values within a row. Values not sharing common superscripts are significantly different (the GT-2 test, p <
0.05).
Table 2 Limb phenotypes exhibited by embryos of p53
+/- mice treated with CP
Doses of cyclophosphamide 12.5 mg/kg CP 20 mg/kg CP 40 mg/kg
Number of tested embryos 80 92 61
Type of anomalies Fetuses with malformed limbs
§
Digit anomalies1arcsine,
mean ± SE
Forelimbs 6 (7.5%) 24 (26.1%) 59 (96.7%)
17.7 ± 3.5
a 32.4 ± 3.1
b 73.0 ± 0.5
c
Hindlimbs 23(28.8%) 66 (71.7%) 61 (100%)
32.5 ± 3.5
a* 55.9 ± 3.8
b* 78.9 ± 0.3
c
Limb reduction anomalies,
arcsine, mean ± SE
Forelimbs 0 0 0
9.9 ± 0.3 10.7 ± 0.4 11.0 ± 0.3
Hindlimbs 0 24 (26.1%) 61 (100%)
9.9 ± 0.3
a 32.4 ± 3.1
b* 78.9 ± 0.3
c*
1Digit anomalies that were registered included syndactyly, ectrodactyly, adactyly. Limb reduction anomalies included amelia, apodia and hemimelia.
§No fetuses with digit and limb anomalies were found in litters of control mice. Superscripts denote results of statistical analysis of values within a row. Values
not sharing common superscripts are significantly different (the GT-2 test, p < 0.05).
*Differences between the fore- and hindlimbs are statistically significant (Student’s t-test, p < 0.05).
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induced 2-fold increase in miRNA-34a expression in the
forelimbs of p53
-/- embryos. In the limbs of embryos
exposed to 40 mg/kg CP the expression pattern of the
miR was identical to that registered in the limbs of
embryos exposed to 20 mg/kg CP (Figure 1). No differ-
ences in the levels of miRNA-34a expression were
observed in fore- and hindlimbs of control p53
+/+ and
p53
-/- embryos (data not presented).
Influence of CP on miRNA-34b and miRNA-34c expression
The expression of miRNA-34b and miRNA-34c was not
altered in the limbs of embryos exposed to 12.5 mg/kg
CP (Figure 1). When females were treated with 20 mg/kg
CP, the level of miRNA-34b and miRNA-34c expression
in the limbs of p53
+/+ embryos were statistically signifi-
cantly higher than that in the limbs of controls but
obviously lower than miRNA-34a levels. Besides, this
dose of CP resulted in a statistically significant increase
in miRNA-34c expression in the forelimbs of p53
-/-
embryos. Finally, the expression pattern of these miRNAs
in the limbs of embryos exposed to 40 mg/kg CP did not
differ from that registered in the limbs of embryos
exposed to 20 mg/kg CP (Figure 1). No differences in the
levels of miRNA-34b and miRNA-34c expression were
observed in fore- and hindlimbs of control p53
+/+ and
p53
-/- embryos (data not presented).
Influence of CP on miRNA-155 and miRNA-125b
expression
The only observed effect on miRNA-155 and miRNA-
125b expression was in the limbs of p53
+/+ embryos
exposed to 40 mg/kg CP. A 1.7 - 2-fold decrease
in the expression level of these miRNAs was registered
(Figure 1). No differences in the levels of miRNA-155 and
miRNA-125b expression were observed in fore- and hin-
dlimbs of control p53
+/+ and p53
-/- embryos (data not
presented).
Discussion
The objectives of this study were formulated as follows: 1)
to evaluate whether CP-induced teratogenic insult alters
the expression of several miRNAs (miRNA-34, miRNA-
125b and miRNA-155) in mouse embryonic limbs and to
Table 3 Effects of p53 on CP-induced limb phenotype (dose of 20 mg/kg)
Tested embryonic structure p53 genotype Number of tested embryos Number of embryos exhibiting:
Digit anomalies Limb reduction anomalies
Forelimbs +/+ and +/- 64 24(37.5%) 0
-/- 28 0* 0
Hindlimbs +/+ and +/- 64 62 (96.9%) 24 (37.5%)
-/- 28 4 (14.3%)* 0*
Differences between p53 positive and p53 negative embryos are statistically significant (the Fisher exact test, p < 0.05).
Figure 1 Expression of miRNA-34, miRNA-125b and miRNA-155
in the forelimbs (FL) and hindlimbs (HL) of p53
+/+ and p53
+/+
embryos of mice exposed to different doses of CP. Samples
were run in triplicate. Relative levels of the miRNAs were calculated
using the 2
-ΔΔCT method (U6B was used as an endogenous control).
Results were analyzed statistically using the GT2 test for multiple
comparisons (n = 4, k = 12) and presented as95% comparison
intervals for the means. Means with intervals that do not overlap
are significantly different. Means with intervals, which do not reach
1 (the level of expression in controls), differ significantly from
controls.
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to estimate how CP-induced alterations in the expression
of the miRNAs correlates with CP-induced limb pheno-
types. We observed that the expression of all tested
miRNA-34 family members was elevated in the limbs of
CP-treated p53
+/+embryos. These data are in agreement
with those obtained in earlier studies that addressed the
effect of p53 on miRNA-34 expression in mice exposed to
ionizing radiation [29,30]. Interestingly, miRNA-34a was
identified as being strongly regulated by p53 regardless of
cell type or stress [31], and in our study, the magnitude of
CP-induced activation of miRNA-34a in the limbs
of p53
+/+ embryos was also significantly higher than that
of miRNA-34b and miRNA-34c. Yet, in the studies cited
above and studies addressing the expression of miRNA-
34a only [32], DNA-damaging stress-induced activation of
the miRNA-34 family was found to be highly p53 depen-
dent. By contrast, in our work, miRNA-34a and miRNA-
34c were found to be activated not only in the limbs of
CP-treated p53
+/+ embryos but also in the forelimbs of
CP-treated p53 knockout embryos. As the expression level
of miRNA-34a was significantly higher in the former, this
observation does not question the role of p53 as a bona
fide mediator of CP -induced activation of miRNA-34a.
Interestingly, however, miRNA-34c expression was practi-
cally identical in the limbs of CP-treated p53
+/+ and p53
-/-
embryos. Altogether, our data demonstrate for the first
time that in some embryonic tissues p53-independent
mechanisms may exist, contributing to teratogen-induced
activation of miRNA-34a and miRNA-34c. (After the
manuscript was submitted for publication, evidence
appeared demonstrating p53-independent activation of
miRNA-34a in primary human TIG3 fibroblasts during
oncogene-induced senescence [33]).
Whereas the levels of miRNA-34 increased in CP-trea-
ted embryos, miRNA-125b and miRNA-155 levels
clearly tended to decrease in the limbs of p53
+/+embryos
exposed to 40 mg/kg CP. We have not encountered any
publications addressing the expression of miRNA-155
in teratogen-treated embryos. As to miRNA-125b, its
expression was found to be decreased in embryos of
female rats treated with such a teratogen as retinoic
acid [34]. Two other teratogens, ionizing radiation and
camptothecin [35], have been shown to suppress
miRNA-125b expression in zebrafish embryos [36]. Our
results concur with the above observations and, in paral-
lel, for the first time, demonstrate that teratogen-
induced suppression of miRNA-125b and miRNA-155
may be p53 dependent.
The analysis of studies addressing the biological activ-
ities of miRNA-34, miRNA-125b and miRNA-155
strongly suggests that all tested miRNAs may be involved
in the mechanism of determining the response of the
embryo to CP-induced teratogenic stimuli. Indeed,
apoptosis and suppression of cell proliferation are key
intermediate cellular events in CP teratogenesis
[16,22,28], and our studies indicate that p53 acts to
intensify these events [16]. The miRNA-34 is activated by
p53 being able to mediate p53-induced proapoptotic and
antiproliferative effects. Besides, recent observations sug-
gest the ability of miRNA-34a to indirectly increase p53
activity [37]. Finally, we observed miRNA-34a and
miRNA-34c activation in the forelimbs of CP-treated p53
knockout embryos. In this context, it is noteworthy that
p53-independent mechanisms of miRNA-34a-induced
apoptosis were suggested [38]. It also supposes that
miRNA-34a may act in cooperation with miRNA-34c,
which is predicted to have the same seed regions and
mRNA targets [31]. A recent study reinforces this propo-
sition: cells exposed to a DNA double-strand break agent
( d o x o r u b i c i n :D O X )d e m o n s t r a t e dt h a to n l ys i m u l t a -
neous inhibition or forced expression of miRNA-34a and
miRNA-34c resulted in the inhibition or induction of
DOX-mediated apoptosis [39]. These observations see-
mingly suggest the possibility of miRNA-34a and
miRNA-34c mediating CP-induced apoptosis in the fore-
limbs of p53
-/- embryos. On the other hand, unlike
miRNA-34 ability to act in concert with p53, miRNA-
125b and miRNA-155 seem to have the potential to func-
tion as inhibitors of CP-induced p53-mediated apoptosis.
Indeed, it has been shown that miRNA-155 suppresses
the expression of the tumor protein 53-induced nuclear
protein 1, which induces apoptosis and cell arrest in sev-
eral cell lines [40]. Furthermore, there exist data implying
that miRNA-155 can be a blocker of caspase 3 activation
[24,25], which in turn is activated by teratogenic doses of
CP in a p53-dependent fashion [16]. As to miRNA-125b,
it was recently suggested to be a bona fide negative regu-
lator of p53 in zebrafish and humans [36]. Finally, as
miRNA-155 and miRNA-125b exhibited similar expres-
sion patterns, an intriguing question was whether CP-
induced suppression of these miRNAs can intensify p53-
mediated apoptosis employing shared targets of these
miRNAs. To address this question, we employed three
independent miR target prediction databases: TatgetScan
[41] TargetRank [42] and PITA [43] and then crossed
these data to find high-confidence putative targets. As a
r e s u l t ,f i v eg e n e s ,s u c ha sS O X 1 1 ,K C N A 1 ,E 2 F 2 ,E T S 1
and MAP3K10, were predicted as common targets for
miRNA-125b and miRNA-155. Two of them have the
potential to intensify p53-mediated apoptosis. The first
one is ETS1, which is suggested to be required for p53
transcriptional activity [44]. The second, MAP3K10, was
shown to induce P53-mediated apoptosis following phos-
phorylation [45].
I nt h el i g h to ft h ea b o v ed a t a ,t h ea c t i v a t i o no f
miRNA-34 and suppression of miRNA-125b and
miRNA-155 in the limbs of CP-treated embryos may be
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sis and, hence, CP-induced limb dysmorphogenesis.
Yet, if we analyze how the changes in the expression
profile of the miRNAs correlate with the severity of the
CP-induced teratologic phenotype, the above suggestion
is compromised. Indeed, in the limbs of embryos
exposed to 20 and 40 mg/kg CP, the expression profile
of these miRNAs was identical although the higher dose
affected limb development much stronger. Also, at all
dose levels, the hindlimbs of the embryos were more
severely affected than the forelimbs. Yet, the levels of
miRNA-34, miRNA-125b and miRNA-155 expression
were found to be practically identical in the hindlimbs
and the forelimbs of p53-positive embryos. In addition,
an elevated expression of miRNA-34a and miRNA-34c
was detected only in less teratologically sensitive fore-
limbs of p53 negative embryos. Together, these findings
scarcely allow suggesting that these miRNAs mediate
CP-induced limb dysmorphogenesis. If it is the case,
what is a possible explanation of this discrepancy?
A plausible explanation may be found if we bear in
mind the concept proclaiming that the main function of
miRNAs is to confer robustness to developmental pro-
grams [46-48]. Within this concept, the main function of
miRNAs positively regulating apoptosis in the embryo
may be formulated as preventing the birth of malformed
offspring. These miRNAs may perform this function by
either mediating an “adaptive apoptosis” which will con-
tribute to the renewal of teratogen-targeted cell popula-
tions by promoting the removal of injured cells or
activating teratogen-induced apoptosis in order to kill
severely malformed embryos. If this is the case, a model
may be proposed in which the activation of some proa-
poptotic miRNAs may represent an adaptive response to
teratogenic apoptotic stimuli, whereas other proapoptotic
miRNAs are activated and/or antiapoptotic miRNAs are
suppressed to strengthen teratogen-induced apoptosis.
This model does not contradict results obtained from
teratological studies implying that proapoptotic signaling
may be indispensable for embryo protection again terato-
genic stress [11]. It is also in agreement with the sugges-
tion that miRNAs are ideal candidates for the
safeguarding of organisms during environmental stresses
[48,49]. Finally, within the context of this model, some of
the results can be partially explained. Indeed, only
miRNA-34a was activated in p53
+/+ embryos exposed to
12.5 mg/kg CP. Of note, this miRNA is suggested to be
the most stress-sensitive member of the miRNA-34
family [31], whereas the dose of 12.5 mg/kg is a threshold
teratogenic dose for these embryos. A further increase in
miRNA-34a expression and an elevated expression of
miRNA-34b and miRNA-34c were detected in p53
+/+
embryos exposed to 20 mg/kg, a dose, to which a part of
embryos are still able to resist. At the same time, the
expression pattern of the miRNA-34 did not change in
embryos exposed to a dose of 40 mg/kg severely affecting
all embryos. Instead, the expression of miRNA-125b and
miRNA-155 having the potential to negatively regulate
the p53-mediated proapoptotic signaling was suppressed.
Remarkably, the observation that the expression pattern
of all tested miRNAs was identical in the forelimbs and
hindlimbs of CP-treated p53
+/+ embryos does not contra-
dict the proposed model.
Conclusion
This study demonstrates that teratogen-induced limb dys-
morphogenesis may be associated with alterations
in miRNA-34, miRNA-125b and miRNA-155 expression.
It also suggests for the first time that in some embryonic
tissues p53-independent mechanisms may exist, contribut-
ing to teratogen-induced activation of miRNA-34a
and miRNA-34c, whereas teratogen-induced suppression
of miRNA-125b and miRNA-155 expression may be
p53 dependent. Finally, the analysis of correlations
between the expression pattern of the tested miRNAs and
CP-induced limb phenotypes allows us to hypothesize that
miRNAs regulating apoptosis may differ from each other
with respect to their functional role in teratogenesis. Some
miRNAs may act to protect embryos, whereas other miR-
NAs may boost a teratogen-induced process of maldeve-
lopment thus inducing embryonic death. This hypothesis
should be taken into account in further studies addressing
the role of miRNAs in teratogenesis.
Methods
Animals and CP treatment
Breeding pairs of p53 knockout mice bearing a mutation
deleting 40% of the p53- coding region and completely
blocking production of p53 protein [50] were received
as a gift from Prof. Moshe Oren (Weizmann Institute of
Science, Israel), and now a colony of these mice is being
maintained in Tel Aviv University Animal Facility on a
14 h light: 10 h darkness cycle by crossing p53
+/-
females with p53
-/- males. To obtain pregnancies,
3-month-old p53
+/- females were caged with p53
+/-
males for 3 h, from 0700 to 1000 h (darkness), and the
presence of a vaginal plug (1100 h) was designated as
day 1 of gestation. CP (Sigma) was injected intraperito-
neally at 1000 h of day 12 of gestation at 12.5, 20 or 40
mg/kg CP (in 0.5 ml saline/20 g body weight). Pregnant
females injected with saline (0.5 ml/20 g bodyweight)
were used as a control throughout the study. Animal
experiments were approved by the Ethics Committee for
Animal Use of Tel Aviv University.
Genotyping
Genotyping of embryos was performed as described else-
where [16]. Briefly, DNA was extracted from the amnion
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DNA, and 3 primers (Sigma): 5’-ACAGCGTGGTGG-
TACCTTAT-3’,5 ’-TATACTCAGAGCCGGCCT-3’,a n d
5’-CTATCAGGACATAGCGTTGG-3’ [50] under the fol-
lowing conditions: initial preheating at 94 8C for 3 min
followed by 30 cycles of the following three steps: 1) dena-
turing (94 8C) for 30 s, 2) annealing (55 8C) for 30 s,
and 3) extension (72 8C) for 1 min followed by 3 min at
72 8C. PCR products were diluted in a DNA-loading buf-
fer and loaded on 1.2% agarose gel diluted in a TBE buffer
with ethidium bromide (Sigma).
Teratological testing
The spectrum of external anomalies induced by CP in
mice is very wide [51]. Our choice of the forelimbs and
hindlimbs as targets was based on our and other studies
demonstrating that these organs are extremely but differ-
entially sensitive to the teratogen (the hindlimbs exhibit
higher sensitivity) [22,52,53]. To evaluate the CP-induced
limb teratologic phenotypes, females were sacrificed by
cervical dislocation on day 16 of gestation, the uteri were
removed and implantation sites, resorptions and live
embryos were recorded. Live fetuses were fixed in
Bouin’s solution, and examined visually for structural
anomalies such as adactyly, ectrodactyly, syndactyly (digit
anomalies) as well as more severe limb reduction anoma-
lies such as, apodia, hemimelia and amelia. As we pre-
v i o u s l ys h o w e d ,t h er e s p o n s eo fp 5 3
-/- embryos to
CP-induced teratogenic stimuli strikingly differs from
that demonstrated by p53
+/+ and p53
+/- embryos, which,
in turn, are equally sensitive to the teratogen [16]. There-
fore, the results characterizing teratogenic response of
p53
+/+ and p53
+/- embryos were pooled.
miRNA analysis
Evaluation of the expression of miRNA-34, miRNA-
125b and miRNA-155 was performed in the fore- and
hindlimbs of p53
+/+ and p53
-/- embryos collected 24
hours after CP injection. The choice of this time point
was based on our previous studies [16,23] that revealed
that embryos tested 24 hours after CP treatment exhib-
ited not only prominent apoptosis but also the highest
levels of the expression of such proapoptotic molecules
as caspases 3, 8 and 9, the strongest suppression of
DNA-binding activity of an anti-apoptotic molecule, the
transcription factor NF-kB, and the lowest levels of the
expression of molecules acting in the classical NF-kB
signaling pathway such as IKKb,I k B a,I - k B b and I-kBε.
To obtain a tested sample, embryos collected from five-
six litters were pooled. The expression of the miRNAs
was tested in four samples obtained for control and
experimental groups.
RNA extraction
Extraction of miRNA-enriched total RNAs was per-
formed using QIAGEN’s RNeasy Plus Mini Kit (QUIA-
GENE, Hilden, Germany) following the manufacturer’s
protocol with slight modifications. Briefly, a tested
embryonic structure was homogenized using RLT lysis
buffer mixed with b-mercaptoethanol. The homogenate
was transferred to a gDNA Eliminator spin column.
Then, the lysate obtained was added with 1.5 volumes
of 100% ethanol, transferred to a filter spin column and
washed twice in order to increase RNA quality. Finally,
RNA was eluted with nuclease-free water and the sam-
ple was evaluated for quality and quantity by ND-1000
according to the manufacturer’s V3.5 User’sM a n u a lf o r
the NanoDrop® ND-1000 Spectrophotometer (Nano-
Drop Technologies, Wilmington, DE).
Quantitative Real-Time PCR
In order to test the integrity of the small RNA fraction
i no u rs p e c i m e n sp r i o rt om iRNA profiling, we per-
formed quantitative analysis of a non-coding small
RNA, U6 RNA as described below. Based on results
obtained, it is reasonable to assume that miRNAs are
intact and could be accurately quantified in the tested
specimens. Real-Time PCR samples were prepared using
a TaqMan PCR master mix and specific real-time pri-
mers for the tested miRNAs (ABI) according the manu-
facturer’s protocol with slight modifications using ABI
7900HT fast real-time PCR system. Briefly, 7 μlr e a l -
time mixture containing 0.5 μl RT product, 0.35 μlr e a l -
time primer (including a probe, the forward and reverse
primers) and 1× TaqMan Universal PCR Master Mix
was prepared. The mixture was incubated in a 384-well
plate at 95°C for 10 min, followed by 40 cycles of 95°C
f o r1 5sa n d6 0 ° Cf o r1m i n .A l lr e a c t i o n sw e r er u ni n
triplicates. miRNA expression levels were calculated by
using the ABI 7500 Real-Time PCR SDS 1.2 software
(ABI). The 2
-ΔΔCT method [54] was used to calculate
relative expression of the tested miRNAs.
Statistical analysis
Statistical analysis of the teratological data was performed
on a litter basis using the GT2-method for multiple com-
parisons [55]. For this, values characterizing the propor-
tions of resorptions and malformed fetuses in each litter of
each group were transformed to arsine values by Freeman-
Tukey’s method as described elsewhere [56] and the
means and standard errors of these indices were calculated
for each group. To look for an association across treat-
ment groups, embryonic genotypes and teratologic pheno-
types, the c
2 test was run as described [57]. GT2-method
for multiple comparisons was used to analyze statistically
Gueta et al. BMC Developmental Biology 2010, 10:20
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Page 7 of 9data characterizing the expression of the miRNAs. The
two-tailed level of significance of differences was equal to
0.05 for all tested parameters.
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